摘要
31ais contribution discusses the use of statins (HMG-CoA reductase inhibitors), aspirin and antihypertensive drugs in secondary and primary prevention of coronary heart disease(CHD), focusingon the rationale for and practical aspects of CI-ID risk assessmentin targeting these treatments.
